Drug Development

With a fresh $190M, Osanni Bio is pioneering a radical new model for drug discovery—building an ecosystem of specialized spinoffs to accelerate cures.

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Zevra Therapeutics' new data for MIPLYFFA in infants with NPC is more than a medical update; it's a key commercial milestone to widen its market.

Veristat isn't just hiring; it's assembling a brain trust to conquer biotech's toughest frontiers. Here's the story behind its strategic talent grab.

An FDA fast-track for a devastating brain disease drug is a beacon of hope for patients and a major validation of Alphabet's long-term biotech strategy.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

With a promising drug, fresh cash, and a new board member known for billion-dollar exits, Avalo Therapeutics is signaling a major strategic shift.

Nippon Shinyaku and Boston Children's Hospital deepen their pact, combining corporate might with research prowess to create new therapies for rare neurology.

A Boston biotech advances a first-in-class antibody into trials, aiming to halt the cellular engine of fibrosis that drives chronic kidney disease.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

The European Commission has approved MAVIRET for acute Hepatitis C, a move set to streamline patient care and accelerate progress against a silent epidemic.

AbbVie's blockbuster SKYRIZI wins European approval for pediatric psoriasis, unlocking a new market and offering a new standard of care to young patients.

With a sub-$10M market cap and blockbuster data, IMUNON's CEO faces a critical test: convince Wall Street its ovarian cancer drug is the real deal.

Ottawa's quiet $892K investment in a Vancouver biotech firm is more than a grant; it's a calculated move to secure Canada's food supply from a post-antibiotic crisis.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.

Parexel's new biotech incubator isn't just another funding vehicle. It's a strategic move to embed regulatory expertise at the seed stage, betting that early guidance is more valuable than capital alone.

As Kyverna eyes a first-in-class approval for its CAR T-cell therapy, it brings in a legal and compliance veteran with a prosecutor's edge to clear the path.